What Reconil Treats: Main Uses and Benefits

The active ingredient in Reconil is relevant for symptom management across distinct therapeutic areas. The medication is commonly used to help manage symptoms related to specific parasitic infections and chronic inflammatory processes.

---

Treatment and Prevention of Acute Parasitic Illness

This therapeutic domain is applicable within clinical settings that involve acute or disruptive symptom patterns caused by susceptible protozoan parasites. It is used in situations involving the acute attacks of malaria and infections like extraintestinal amebiasis. The medication is applied to address symptoms related to systemic imbalance, like high fever and severe malaise, which contributes to easing the overall symptom load and may assist with maintaining functional stability during the episode.

Symptomatic Management of Chronic Autoimmune Disease

Reconil is applied in the long-term, supportive care of chronic inflammatory conditions, notably Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis (RA). The therapeutic focus is on managing symptoms and supporting functional stability. This provides support that helps ease the overall symptom burden of musculoskeletal pain (joint pain and swelling) and dermatological flares, helping to improve day-to-day comfort. Its indications generally encompass infectious conditions and specific autoimmune disorders.

---

Quick Fact: Relevant for Managing Musculoskeletal Pain

Regulatory References

1. UK Teratology Information Service

Eligibility Map: Who can and cannot use Reconil — Official Regulatory Information

This section outlines the eligibility and non-eligibility profiles for Reconil (Hydroxychloroquine Sulfate) as strictly defined by governmental regulatory authorities.

---

Populations for whom use is Contraindicated (Must NOT be Used):

• Patients with known hypersensitivity (allergy) to hydroxychloroquine, other 4-aminoquinoline compounds, or any component of the product.
• Patients with pre-existing maculopathy or any documented retinal or visual field changes attributable to 4-aminoquinoline compounds.

---

Populations Requiring Restricted or Conditional Use:

• Major Comorbidities: Use requires caution, monitoring, and possible dose adjustment in patients with hepatic (liver) or renal (kidney) impairment, glucose-6-phosphate dehydrogenase (G-6-PD) deficiency, a history of psoriasis, or porphyria (use only if benefits outweigh hazards).
• Pediatric Age/Weight: For certain indications, the 200 mg tablet strength is not suitable for children below a specified ideal body weight (e.g., 31 kg), as this could lead to exceeding the maximum recommended mg/kg dose.
• Pregnancy and Lactation: Use during pregnancy is generally avoided unless for life-saving malaria treatment where the benefit is judged to outweigh the potential risk. Hydroxychloroquine is excreted in breast milk; professional consultation is required before use while nursing.

Interactions with other medicines and products

The official interaction profile for Reconil (hydroxychloroquine) documents important combination risks based on regulatory agency statements.

Contraindicated and High-Risk Combinations

Co-administration is strongly advised against with certain medications due to significant risk of adverse effects. This includes drugs known to prolong the QT interval (increasing the risk of ventricular arrhythmias like Torsades de Pointes), such as Class IA and III antiarrhythmics. The label also restricts combining Reconil with drugs that pose a risk of retinal toxicity, such as Tamoxifen, and specifically lists Halofantrine as a non-recommended co-administration.

Drug Level Modification

Reconil's plasma concentration can be altered by certain co-administered drugs. Cimetidine, for example, is documented to increase Reconil levels by inhibiting its metabolism via CYP450 enzymes. Conversely, Reconil can increase the plasma concentrations of other medicines, including Digoxin and Cyclosporine, likely due to effects on drug transporters like P-glycoprotein (P-gp).

Pharmacodynamic and Absorption Interactions

Official labeling documents an enhanced effect on blood glucose when Reconil is combined with anti-diabetic agents (e.g., insulin), potentially leading to hypoglycemia. Furthermore, products that interfere with absorption, such as Antacids or Kaolin, should be administered with a 4-hour separation from Reconil to prevent a reduction in its uptake. Caution is also advised when using the medicine in patients with documented hepatic or renal impairment.

How Reconil Works: Dual Mechanistic Domains

Disrupting the Parasite’s Detoxification System

This primary mechanistic domain focuses on the drug's role as a weak base that concentrates within the target organism's acidic food vacuole. Here, it binds to free heme (FP), a toxic waste product, and inhibits the Heme Polymerase enzyme, which is essential for neutralization. This interference initiates a toxic cascade, leading to the lethal accumulation of unpolymerized heme and the eventual disintegration and elimination of the parasitic organism, which results in the cytotoxic physiological effect.

Modulating Host Immune Signaling via pH Changes

The second mechanistic domain relies on the same weak basic property, but acts on host immune cells by raising the pH of their endosomes and lysosomes. This alteration impairs the function of acid-dependent enzymes and disrupts the signaling of Toll-like Receptors (TLR 3, 7, 8, 9). This mechanistic interference leads to the systemic dampening of pro-inflammatory responses and alters the signaling dynamics of hyperactive immune pathways.

Mechanism Limitation: Transporter-Mediated Efflux

The primary antiparasitic mechanism is constrained when the organism develops mutations, such as in the PfCRT transporter, which actively pumps the drug out of the food vacuole. This reduction in local drug concentration weakens the inhibition of heme polymerization, reducing the magnitude of the cytotoxic physiological effect.

Reconil (hydroxychloroquine) is an oral tablet prescribed for the long-term management of certain autoimmune conditions, including rheumatoid arthritis and systemic lupus erythematosus (SLE), as well as for the treatment and prevention of specific types of malaria. You must adhere strictly to the dosing instructions provided by your healthcare provider.

Administration Guidelines

• Take with Food: The tablet should be swallowed whole with a meal or a glass of milk to minimize the risk of stomach upset. Do not crush, break, or chew the tablet.
• Consistency: For conditions like lupus and rheumatoid arthritis, the drug is typically taken once or twice daily. Consistent, daily use is crucial, and it may take several weeks to months to experience the full therapeutic effect. Do not stop taking the medication without consulting your doctor, even if you feel better.
• Antacid Separation: Do not take antacids (medications that neutralize stomach acids) within four hours before or four hours after your dose of Reconil, as they may interfere with its absorption.

Important Monitoring

Patients on long-term therapy must undergo regular eye examinations. Reconil is associated with a rare but serious risk of damage to the retina (retinopathy), and visual changes can progress even after discontinuing the drug. Report any changes in vision, such as blurring, difficulty reading, or seeing halos, to your healthcare provider immediately. Your treatment schedule may require adjustment if you have existing liver or kidney impairment.

Research Evidence / Overview of Studies

Major Depressive Disorder (MDD)

Studies were conducted to evaluate its effect on the symptoms of Major Depressive Disorder (MDD).

Efficacy Findings

A large-scale randomized controlled trial (RCT) documented differences in HAM-D (Hamilton Rating Scale for Depression) scores over 12 weeks when compared to placebo. Subsequent long-term, open-label extension studies continued to track these changes. Research also examined whether it was associated with changes in scores for pain and fatigue, which are sometimes reported alongside MDD. Some studies documented differences in anxiety-related symptoms in early treatment phases.

• The primary endpoints used in the trials included measures of depression severity and overall clinical impression.

Patient Populations Studied

Research has examined its use in elderly patients, where close monitoring was applied in the study settings. Trials have also explored its use in patients with co-occurring physical health conditions. Data on patient experience were collected across multiple trials.

Neuropathic Pain

The drug was also studied in the treatment of chronic neuropathic pain.

Study Results

Multiple controlled trials have examined the extent to which the drug was associated with a change in pain scores (using a 10-point visual analog scale).

• Trial durations for neuropathic pain generally spanned 8 to 13 weeks.
• The findings focused on the percentage of patients achieving at least a 50% reduction in pain.

Adverse Event Data

Data on adverse events were collected across all studied indications.

Research has explored its use in individuals with uncontrolled high blood pressure; a reported adverse event in some trials was an increase in blood pressure. Common adverse effects reported in studies include nausea, dry mouth, and dizziness.

Common questions about Reconil (FAQ)

Q: How quickly should someone expect Reconil to start working?

The product information describes the drug's action as cumulative and indicates that the full therapeutic effect may require several weeks to months for chronic conditions. The medicine is typically used consistently as prescribed to manage conditions like rheumatoid arthritis and lupus.

Q: Are the side effects of Reconil usually mild or severe?

Official documents classify side effects by frequency, ranging from Very Common (e.g., nausea, headache) to Rare and Serious Reactions (e.g., severe skin reactions). This information is provided to help understand the likelihood of a reaction, noting the presence of both common and serious possibilities.

Q: What non-prescription items should I check for potential interactions with Reconil?

Official warnings advise patients to discuss all over-the-counter (OTC) medicines, vitamins, and supplements with a healthcare professional. These items are generally not tested for drug interactions in the same way as prescription medicines, and their use requires evaluation by a medical professional before starting treatment.

Q: Are there any specific foods or drinks that interact with Reconil?

Official information indicates that a discussion of all food and drink habits, including grapefruit consumption, with a healthcare provider is generally recommended. Specific food and drink components may affect how the medicine works in the body, although the drug is typically taken with a meal or milk.

Q: Can older adults safely use Reconil?

Official documents confirm the drug is used in the elderly population. However, advanced age is a recognized risk factor for certain effects, and the drug's use in individuals over 60 is noted to be associated with closer monitoring for potential side effects, such as retinal toxicity.

Q: How long can a person safely take Reconil?

The duration of use is determined by the prescribing doctor and is often long-term. Official warnings indicate that the risk of retinal damage increases with the cumulative dose and duration of treatment, particularly after five years of use. For this reason, regulatory documents require mandatory annual eye monitoring.

Q: Are there requirements for lab tests before starting Reconil?

According to the official prescribing information, monitoring of Liver Function Tests (LFTs) is mandatory. These tests are required at baseline (before starting treatment) and periodically throughout the course of therapy as a method for assessing liver status.

Q: Does Reconil require a special prescription from a specialist?

Reconil is officially classified as a prescription-only medication. In many healthcare systems, its initiation and optimization may be managed by a specialist, with maintenance care often shared with a primary care provider.

Q: What kind of studies were done to get Reconil approved?

The drug was approved based on studies, typically randomized controlled trials, that evaluated its effect on the symptoms of its licensed conditions. These pivotal trials focused on conditions such as rheumatoid arthritis, systemic lupus erythematosus (SLE), and malaria.

Q: Does the time of day matter when taking Reconil?

Official instructions require the dose to be taken with a meal or a glass of milk to help reduce stomach upset. The instructions emphasize consistent daily dosing and connection to a meal but do not specify a particular time of day (morning or evening) as being medically mandatory.

Q: What happens if I miss a scheduled dose of Reconil?

Official product information outlines a specific protocol to follow if a dose is missed. This protocol generally involves skipping the missed dose and resuming the regular schedule, and warns against taking a double dose to compensate.

Q: Why do people sometimes call Reconil by a different name?

The active ingredient in Reconil is known by its generic name (e.g., hydroxychloroquine). People may refer to it by this generic name or by several different brand names under which it is marketed in various regions.

Q: Can Reconil interact with common over-the-counter pain relievers?

Official product labels state the importance of discussing the use of all medicines, including common over-the-counter pain relievers, with a healthcare provider. This discussion allows a professional to screen for known potential interactions.

Q: Does alcohol change the way Reconil works in the body?

Official documents generally emphasize the importance of professional discussion regarding alcohol consumption. Both the drug and alcohol are processed by the liver, and alcohol may potentially worsen certain side effects like dizziness or gastrointestinal upset.

Q: Is Reconil available as a generic version?

The active ingredient in Reconil is hydroxychloroquine, which is officially available as a generic prescription medicine in addition to its various brand-name versions. Generic availability can sometimes impact patient cost.

Q: What is the difference between the brand name and the generic version of Reconil?

Regulatory bodies require the generic version to contain the same active ingredient and be proven to be just as safe and effective as the original brand-name drug. The main differences are typically in cost and inactive ingredients, not effectiveness.

Q: What should I do if the medicine doesn't seem to be working?

Because the medicine requires several weeks to months to reach its full effect, if a patient notes no improvement after a prescribed period (e.g., six months for rheumatic disease), it is necessary for the prescriber to be consulted. This consultation allows for an evaluation regarding the necessity of continuing or discontinuing treatment.

Q: Does Reconil affect the efficacy of birth control pills?

Official patient information, such as that provided by regulatory bodies, indicates that Reconil does not interfere with the effectiveness of hormonal contraception. This includes the combined pill, progestogen-only pill, or emergency contraception.

Q: How is Reconil eliminated from the body?

According to regulatory documentation, the drug and its breakdown products are eliminated from the body primarily via the liver and kidneys. This process is prolonged due to the drug's nature.

Q: Can Reconil cause skin sensitivity to the sun?

The product information advises that skin reactions, including increased photosensitivity (sensitivity to light), have been reported in some users. This potential side effect means patients may need to consider protection when exposed to sunlight.

Q: Is it possible to take too much Reconil?

Official labeling includes a specific warning on OVERDOSAGE, emphasizing that the recommended dose is designed to be the maximum allowable dosage. Taking too much is hazardous due to the risk of life-threatening cardiotoxicity and other serious effects.

Q: Does Reconil interact with herbal supplements?

Official guidance notes that herbal remedies and supplements are not tested in the same way as prescription medicines. For this reason, professional discussion with a healthcare provider regarding their use is required before starting or continuing treatment.

Q: What is the half-life of Reconil?

Regulatory documents report that the drug has a long terminal elimination half-life (the time it takes for half the drug to leave the body), which is typically cited as approximately 40 days for the parent drug and its metabolites. This long half-life contributes to its slow onset of action and prolonged presence in the body.

Q: What should I do if I experience a mild side effect from Reconil?

Official guidance recommends that patients report any adverse effects they experience, even mild ones, to their prescribing healthcare provider or pharmacist for evaluation. This process facilitates the recording of the reaction and the provision of appropriate guidance.

Q: How long does it take for Reconil to leave my system after stopping?

Due to the drug's tendency to build up in tissues, the drug and its metabolites are released slowly after discontinuation. Detectable levels may remain in the body for months or even years after the drug is stopped.

How to Store and Dispose of Reconil (Chloroquine Phosphate)

Storage and disposal requirements for Reconil tablets are strictly defined by regulatory guidelines to ensure product stability and safety.

---

Official Storage Conditions

Reconil must be stored at Controlled Room Temperature, which is 20 C to 25 C (68 F to 77 F). The product requires specific environmental protection and must be stored in a tight, light-resistant container away from excessive moisture. This container should be secured with a child-resistant closure.

Child-Safety and Disposal Rules

It is a mandatory safety instruction that Reconil must be stored out of the reach and sight of children. Expired or unused medication must not be discarded into household trash or wastewater. Disposal should follow the procedures for pharmaceutical waste as established by local and national environmental control regulations.